4 years ago

LoQus23 Therapeutics Secures £7 Million in Seed Funding for Huntington's Disease Treatments

  • LoQus23 Therapeutics, a UK-based biotech company developing small molecule therapies targeting aberrant DNA mismatch repair (MMR) to treat Huntington’s and other triplet repeat diseases (TRDs), has closed a £7 million extended seed funding round

  • The funding was led by Novartis Venture Fund (NVF) and the Dementia Discovery Fund (DDF), which previously invested £4.5 million in the company in 2019

  • The new funding will enable LoQus23 to identify a small molecule drug candidate for its lead MMR target and explore other MMR proteins for their role in somatic instability in TRDs.

      • ProblemHealthcare

      "Huntington’s and other triplet repeat disorders (TRDs) are currently incurable neurodegenerative diseases caused by unstable DNA sequences."

      Solution

      "LoQus23 Therapeutics is developing small molecule therapies that target aberrant DNA mismatch repair (MMR) to stop the DNA instability and therefore slow neurodegeneration in Huntington's and other TRDs."

      Covered on